Providers

As health care shifts reimbursement models from fee-for-service to value-based care, new terms and phrases have been surfacing across the industry. Two of the terms emerging with increased usage are “patient engagement” and an “active patient.” But what do they mean? And why are they important?

Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected by hidradenitis suppurativa (HS), spoke on the surgical and therapeutic interventions she’s had for the management of HS.

Addressing the mental health crisis in the United States warrants innovation in treatment and recovery, and the development of mechanisms to provide and pay for them accordingly.

Researchers used 2011-2020 data to examine age- and race-/ethnicity-related trends in hypertension diagnosis, with implications for future cardiovascular disease care.

Patients with Parkinson disease reported significant reductions in anxiety when provided with acupuncture vs sham acupuncture for 8 weeks.

Key stakeholders involved in the delivery of cancer care in New Jersey discuss strategies driving innovation in oncology and remaining challenges impeding their integration at the 70th Annual Roy A. Bowers Pharmaceutical Conference.

On this episode of Managed Care Cast, we speak with 2 authors of an article in the September issue of The American Journal of Managed Care®, which focused on the results of their evaluation of an intensive, community-based care management program for dual-eligible Medicaid ACO high-risk patients.

With 6 pegfilgrastim biosimilars approved, and multiple administration options, a patient-centric model of pegfilgrastim administration should be possible for patients with cancer who require prophylaxis of febrile neutropenia.

Streamlining the prior authorization process can improve care accuracy and patient access to care, writes Siva Namasivayam, CEO of Cohere Health.

Russell Rotondo, MD, FACC, medical director of clinical strategy and innovation for cardiology at Cohere Health, discusses the myriad positive ways utilization management programs can have an impact on patient outcomes in cardiovascular care.

Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses clinical recommendations for patients with moderate to severe psoriasis, particularly the need for shared decision-making.

Sutimlimab demonstrated rapid efficacy in the study cohort, and platelet level improvements were sustained for the duration of treatment in nearly half of the participants.

This new study of pulmonary arterial hypertension (PAH) among women examined the in-common symptoms of different disease phenotypes to see where they overlap and ultimately to define the “symptome” according to symptom cluster and characteristics.

Being able to use minimal residual disease (MRD) negativity to make treatment decisions, such as stopping maintenance therapy, can have savings related to cost and quality of life (QOL) for patients, said Ajay Nooka, MD, MPH, FACP, associate professor, Winship Cancer Institute.

Patients with hepatic encephalopathy (HE) often do not seek care until they are in critical condition, making an optimized emergency care process critical to reduce adverse prognosis and improve clinical symptoms.

Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected by hidradenitis suppurativa (HS), discussed the misconceptions she faced from clinicians regarding her clinical symptoms of HS prior to diagnosis.

Three types of salient beliefs were investigated in this study that examined why mothers would or would not participate in depression screening via genetic salivary testing, with the results indicating potential for mental health disparities among diverse populations.

SUNSHINE and SUNRISE trial data will be submitted to the FDA as part of Novartis’ Biologics License Application (BLA) for secukinumab in hidradenitis suppurativa.

Menopause symptoms are not being recognized, leading to misdiagnosis and improper treatment.

Significantly more patients given ruxolitinib cream vs vehicle demonstrated rapid improvements in itch that were sustained over time.

Simply adding an admission screening question and a 2-step testing algorithm sharply decreased the number of Clostridioides difficile infections (CDI) in the year after implementing the interventions.

New data show litifilimab outperformed placebo in patients with active arthritis and skin manifestations due to systemic lupus erythematosus (SLE).

About 4 in 10 patients do not receive curative therapy despite early detection, a new study shows.

The National Comprehensive Cancer Network recommendations come as the FDA weighs an indication in chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) for zanubrutinib.

A new study has found that diabetes-related deaths in rural areas did not decrease for the period of 1999 to 2019, tripling the mortality gap between urban and rural patients with diabetes.

Initiation of antipsychotics was nearly 3 times more common in patients with Parkinson disease vs controls, with the incidence rate found to increase approximately 4 years prior to PD diagnosis.

Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, spoke on diagnostic challenges for atopic dermatitis and tips for clinicians in screening for the condition.

A 16% lower adjusted risk in recurrent Clostridioides difficile infections was found in 2018 compared with 2013 across diverse US sites part of the CDC’s Emerging Infections Program.

Using systemic corticosteroids (SCS) to treat chronic rhinosinusitis with nasal polyps (CRSwNP) has been linked to adverse outcomes among patients, prompting these study investigators to compare their health care resource utilization with that of patients who have CRSwNP but don’t use SCS.

Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected with hidradenitis suppurativa (HS), speaks on the quality of life burden she has experienced during her HS disease journey.